Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NYSE:OGN NASDAQ:PTCT NASDAQ:RTRX NASDAQ:ZLAB On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeOGNOrganon & Co.$9.76+0.6%$9.78$8.01▼$23.10$2.52B0.63.43 million shs3.69 million shsPTCTPTC Therapeutics$52.13+0.0%$49.21$29.01▼$58.38$4.13B0.541.12 million shs1.02 million shsRTRXTravere Therapeutics$15.63+1.2%$26.56$8.98▼$24.96$797.94M0.67412,277 shs764,859 shsZLABZai Lab$36.82-2.6%$36.01$16.01▼$44.34$4.20B1.03809,770 shs602,669 shs The Best Nuclear Energy Stocks to BuyNuclear energy stocks are roaring. It's the hottest energy sector of the year. Cameco Corp, Paladin Energy, and BWX Technologies were all up more than 40% in 2024. The biggest market moves could still be ahead of us, and there are seven nuclear energy stocks that could rise much higher in the next several months. To unlock these tickers, enter your email address below.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceOGNOrganon & Co.+0.67%-4.08%-3.94%+1.67%-55.33%PTCTPTC Therapeutics+0.04%+16.52%+6.06%+4.36%+54.00%RTRXTravere Therapeutics-0.19%-3.13%+5.03%-26.95%+61.95%ZLABZai Lab-2.59%-0.94%+3.75%+18.09%+93.48%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationOGNOrganon & Co.4.8732 of 5 stars3.34.01.73.72.73.32.5PTCTPTC Therapeutics4.4836 of 5 stars4.32.00.04.43.00.81.3RTRXTravere TherapeuticsN/AN/AN/AN/AN/AN/AN/AN/AZLABZai Lab2.217 of 5 stars3.42.00.00.02.11.70.6Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceOGNOrganon & Co. 2.50Moderate Buy$18.0084.43% UpsidePTCTPTC Therapeutics 2.67Moderate Buy$69.3833.10% UpsideRTRXTravere Therapeutics 0.00N/AN/AN/AZLABZai Lab 2.80Moderate Buy$54.2847.41% UpsideCurrent Analyst Ratings BreakdownLatest RTRX, PTCT, OGN, and ZLAB Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails7/29/2025PTCTPTC TherapeuticsTruist FinancialSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetBuy ➝ Buy$80.00 ➝ $86.007/29/2025PTCTPTC TherapeuticsBarclaysSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetEqual Weight ➝ Equal Weight$42.00 ➝ $46.007/29/2025PTCTPTC TherapeuticsBank of AmericaSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetBuy ➝ Buy$68.00 ➝ $84.007/29/2025PTCTPTC TherapeuticsUBS GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetBuy ➝ Buy$71.00 ➝ $80.007/29/2025PTCTPTC TherapeuticsCantor FitzgeraldSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetOverweight ➝ Overweight$112.00 ➝ $120.007/29/2025PTCTPTC TherapeuticsWells Fargo & CompanySubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetOverweight ➝ Overweight$74.00 ➝ $78.007/28/2025PTCTPTC TherapeuticsCitigroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetNeutral ➝ Neutral$40.00 ➝ $50.006/30/2025ZLABZai LabLeerink PartnersSubscribe to MarketBeat All Access for the recommendation accuracy ratingSet Price TargetOutperform ➝ Outperform$73.00 ➝ $75.006/17/2025PTCTPTC TherapeuticsTruist FinancialSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageBuy$80.005/27/2025PTCTPTC TherapeuticsWells Fargo & CompanySubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetOverweight ➝ Overweight$68.00 ➝ $74.005/22/2025OGNOrganon & Co.BNP ParibasSubscribe to MarketBeat All Access for the recommendation accuracy ratingUpgradeStrong-Buy(Data available from 8/2/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookOGNOrganon & Co.$6.40B0.40$4.95 per share1.97$1.83 per share5.33PTCTPTC Therapeutics$806.78M5.12N/AN/A($14.24) per share-3.66RTRXTravere Therapeutics$175.34M4.55N/AN/A$5.15 per share3.03ZLABZai Lab$398.99M10.25N/AN/A$7.68 per share4.79Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateOGNOrganon & Co.$864M$2.883.392.611.0111.92%227.43%7.34%8/5/2025 (Estimated)PTCTPTC Therapeutics-$363.30M$6.518.01N/AN/A33.56%-78.56%32.11%8/7/2025 (Estimated)RTRXTravere Therapeutics-$146.43M-$3.46N/AN/AN/A-49.13%-36.38%-14.90%N/AZLABZai Lab-$257.10M-$2.49N/AN/AN/A-60.26%-33.35%-23.28%8/7/2025 (Estimated)Latest RTRX, PTCT, OGN, and ZLAB EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails8/7/2025Q2 2025PTCTPTC Therapeutics-$1.07N/AN/AN/A$173.01 millionN/A8/7/2025Q2 2025ZLABZai Lab-$0.42N/AN/AN/A$125.66 millionN/A8/5/2025Q2 2025OGNOrganon & Co.$0.93N/AN/AN/A$1.55 billionN/A5/8/2025Q1 2025ZLABZai Lab-$0.50-$0.45+$0.05-$0.45$118.40 million$106.49 million5/6/2025Q1 2025PTCTPTC Therapeutics$0.85$10.04+$9.19N/A$437.16 million$1.18 billionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthOGNOrganon & Co.$0.080.82%N/A2.78%N/APTCTPTC TherapeuticsN/AN/AN/AN/AN/ARTRXTravere TherapeuticsN/AN/AN/AN/AN/AZLABZai LabN/AN/AN/AN/AN/ALatest RTRX, PTCT, OGN, and ZLAB DividendsAnnouncementCompanyPeriodAmountYieldEx-Dividend DateRecord DatePayable Date5/2/2025OGNOrganon & Co.quarterly$0.020.8%5/12/20255/12/20256/12/2025(Data available from 1/1/2013 forward)Compare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioOGNOrganon & Co.16.491.671.15PTCTPTC TherapeuticsN/A3.893.85RTRXTravere Therapeutics0.667.237.14ZLABZai LabN/A3.263.09Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipOGNOrganon & Co.77.43%PTCTPTC TherapeuticsN/ARTRXTravere TherapeuticsN/AZLABZai Lab41.65%Insider OwnershipCompanyInsider OwnershipOGNOrganon & Co.1.96%PTCTPTC Therapeutics5.50%RTRXTravere Therapeutics4.63%ZLABZai Lab4.96%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableOGNOrganon & Co.4,000259.96 million254.86 millionNot OptionablePTCTPTC Therapeutics1,41079.26 million74.90 millionOptionableRTRXTravere Therapeutics22151.05 millionN/ANot OptionableZLABZai Lab1,869111.08 million105.57 millionOptionableRTRX, PTCT, OGN, and ZLAB HeadlinesRecent News About These CompaniesZai Lab Limited Unsponsored ADR (NASDAQ:ZLAB) Sees Significant Increase in Short InterestAugust 2 at 2:19 AM | americanbankingnews.comZai Lab (NASDAQ:ZLAB) Shares Gap Down - Should You Sell?July 31 at 1:15 PM | marketbeat.comTD Asset Management Inc Lowers Position in Zai Lab Limited Unsponsored ADR (NASDAQ:ZLAB)July 31 at 5:01 AM | marketbeat.comZai Lab (ZLAB) Projected to Post Quarterly Earnings on ThursdayJuly 31 at 2:18 AM | marketbeat.comY Intercept Hong Kong Ltd Acquires New Stake in Zai Lab Limited Unsponsored ADR (NASDAQ:ZLAB)July 30 at 5:38 AM | marketbeat.comZai Lab Limited Unsponsored ADR (NASDAQ:ZLAB) Given Consensus Rating of "Moderate Buy" by AnalystsJuly 30 at 2:51 AM | americanbankingnews.comZai Lab (NASDAQ:ZLAB) Shares Gap Up - Time to Buy?July 28, 2025 | marketbeat.comCerity Partners LLC Makes New $420,000 Investment in Zai Lab Limited Unsponsored ADR (NASDAQ:ZLAB)July 27, 2025 | marketbeat.comZai Lab Limited Unsponsored ADR (NASDAQ:ZLAB) Receives Consensus Rating of "Moderate Buy" from BrokeragesJuly 26, 2025 | marketbeat.comZai Lab Ltd (ZLAB) Delivers Positive Results for Potential Gastric Cancer TreatmentJuly 25, 2025 | msn.comZai Lab Limited Unsponsored ADR (NASDAQ:ZLAB) Shares Acquired by Envestnet Asset Management Inc.July 24, 2025 | marketbeat.comZai Lab Limited (ZLAB) Stock Jumps 6.8%: Will It Continue to Soar?July 23, 2025 | zacks.comZai Lab (NASDAQ:ZLAB) Shares Gap Up - Here's What HappenedJuly 22, 2025 | marketbeat.comAllianz Asset Management GmbH Purchases 378,545 Shares of Zai Lab Limited Unsponsored ADR (NASDAQ:ZLAB)July 22, 2025 | marketbeat.comJennison Associates LLC Makes New Investment in Zai Lab Limited Unsponsored ADR (NASDAQ:ZLAB)July 20, 2025 | marketbeat.comZai Lab (NASDAQ:ZLAB) Shares Gap Down - Here's WhyJuly 18, 2025 | marketbeat.comC WorldWide Group Holding A S Sells 40,000 Shares of Zai Lab Limited Unsponsored ADR (NASDAQ:ZLAB)July 18, 2025 | marketbeat.comMarks Group Wealth Management Inc Invests $373,000 in Zai Lab Limited Unsponsored ADR (NASDAQ:ZLAB)July 14, 2025 | marketbeat.comAlps Advisors Inc. Sells 12,097 Shares of Zai Lab Limited Unsponsored ADR (NASDAQ:ZLAB)July 12, 2025 | marketbeat.comZai Lab to Announce Second Quarter 2025 Financial Results and Recent Corporate Updates on August 7, 2025July 10, 2025 | businesswire.comZai Lab (NASDAQ:ZLAB) Shares Gap Down - What's Next?July 8, 2025 | marketbeat.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeRTRX, PTCT, OGN, and ZLAB Company DescriptionsOrganon & Co. NYSE:OGN$9.76 +0.06 (+0.62%) Closing price 08/1/2025 03:59 PM EasternExtended Trading$9.64 -0.12 (-1.18%) As of 08/1/2025 06:32 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Organon & Co. is a science based global pharmaceutical company, which develops and delivers innovative health solutions through a portfolio of prescription therapies within women’s health, biosimilars and established brands. The company was founded on March 11, 2020, and is headquartered in Jersey City, NJ.PTC Therapeutics NASDAQ:PTCT$52.13 +0.02 (+0.04%) Closing price 08/1/2025 04:00 PM EasternExtended Trading$51.61 -0.52 (-1.01%) As of 08/1/2025 06:51 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.PTC Therapeutics, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of medicines to patients with rare disorders in the United States and internationally. The company offers Translarna and Emflaza for the treatment of Duchenne muscular dystrophy; Upstaza to treat aromatic l-amino acid decarboxylas (AADC) deficiency, a central nervous system disorder; Tegsedi and Waylivra for the treatment of rare diseases; and Evrysdi to treat spinal muscular atrophy (SMA) in adults and children. Its development pipeline products include Sepiapterin for the treatment of phenylketonuria; PTC518 splicing platform, which is being developed for the treatment of Huntington's disease; and ferroptosis and inflammation platforms, including vatiquinone to treat Friedreich ataxia and utreloxastat for the treatment of amyotrophic lateral sclerosis. The company distributes its products through third-party distributors. It has collaborations with F. Hoffman-La Roche Ltd, Hoffman-La Roche Inc., the SMA Foundation, National Taiwan University, Akcea Therapeutics, Inc., and Shiratori Pharmaceutical Co., Ltd. PTC Therapeutics, Inc. was incorporated in 1998 and is headquartered in South Plainfield, New Jersey.Travere Therapeutics NASDAQ:RTRXTravere Therapeutics, Inc. is a biopharmaceutical company. It engages in the identification, development, commercialization, and distribution of therapies to people living with rare diseases. Its products include Chenodal, Cholbam, and Thiola. The company was founded by Martin Shkreli on February 8, 2008 and is headquartered in San Diego, CA.Zai Lab NASDAQ:ZLAB$36.82 -0.98 (-2.59%) Closing price 08/1/2025 04:00 PM EasternExtended Trading$36.55 -0.27 (-0.73%) As of 08/1/2025 06:12 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Zai Lab Limited develops and commercializes therapies to treat oncology, autoimmune disorders, infectious diseases, and neuroscience. Its commercial products include Zejula, an orally administered poly polymerase 1/2 inhibitor; Optune, a cancer therapy that uses electric fields tuned to specific frequencies to kill tumor cells; NUZYRA for acute bacterial skin and skin structure infections, and community acquired bacterial pneumonia; Qinlock to treat gastrointestinal stromal tumors, and VYVGART, a human IgG1 antibody fragment for myesthenia gravis. The company also develops Tumor Treating Fields, a portable device for delivery of electric fields; Repotrectinib, a tyrosine kinase inhibitor (TKI) to target ROS1 and TRK A/B/C in TKI-naïve- or -pretreated cancer patients; Tisotumab vedotin, an antibody drug conjugate; Adagrasib for treating KRAS-G12C-mutated NSCLC, colorectal cancer, and pancreatic cancer; and Bemarituzumab to treat gastric and gastroesophageal junction cancer patients. In addition, it develops Sulbactam/durlobactam, a combination of a beta-lactam antibiotic and a beta-lactamase inhibitor for the treatment of serious infections caused by Acinetobacter; KarXT for the treatment of psychiatric and neurological conditions. It has license and collaboration agreement with Tesaro, Inc. to develop, manufacture, and commercialize niraparib; NovoCure to develop and commercialize Tumor Treating Fields; Deciphera to develop and commercialize ripretinib; Paratek Bermuda Ltd. to develop, manufacture, and commercialize omadacycline; argenx, to develop and commercialize efgartigimod; BMS to develop and commercialize tisotumab vedotin and repotrectinib; Mirati to research, develop, manufacture, and commercialize adagrasib; Amgen to develop and commercialize bemarituzumab; and Innoviva to develop and commercialize Sulbactam-Durlobactam; Karuna to develop and commercialize KarXT. The company was incorporated in 2013 and is headquartered in Shanghai, China. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas MarketBeat Week in Review – 07/28 - 08/01 Alphabet Gains Momentum as Sentiment on Wall Street Improves Amazon's Earnings: What Comes Next and How to Play It Apple Stock: Big Earnings, Small Move—Time to Buy? Tesla Teams With Samsung—Will Other Chipmakers Follow? Will Hims & Hers Fall Along With Novo Nordisk? UPS's 7.5% Dividend: A Blue-Chip Stock on a Once-in-a-Decade Sale Is PG&E an AI Power Play? Why Options Traders Are Betting Big Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
